OxyContin maker Purdue Pharma plans to close its manufacturing plant in Durham, N.C., by the end of the year, according to the Stamford Advocate.
Purdue Pharma will sell the facility to Novo Nordisk for an undisclosed amount. It will continue operations at its manufacturing plant in Wilson, N.C.
The embattled drugmaker, which is facing more than 1,000 lawsuits linked to the U.S. opioid crisis, declined to comment on whether the closure and sale will result in layoffs.
"Given the market dynamics and expected demand for our current portfolio of marketed products, the continued operation of [the Durham plant] can no longer be justified," Purdue CEO and President Craig Landau said in a letter to employees, cited by the Advocate. "Further, a thorough analysis of Purdue’s current and future business requirements shows that with additional staffing and the continued leadership of personnel already in place, our Wilson facility is in a position to meet today’s product requirements as well as enable the growth strategy for Purdue and all of its subsidiaries going forward."